Exploring the Barriers to and Facilitators of Using Evidence-Based Drugs in the Secondary Prevention of Cardiovascular Diseases: Findings From a Multistakeholder, Qualitative Analysis

Global Heart

28 Novembre Nov 2017 20 days ago
  • Werba P

Health-system barriers and facilitators associated with cardiovascular medication adherence have seldom been studied, particularly in low- and middle-income countries where uptake rates are poorest. This study sought to explore the major obstacles and facilitators to the use of evidence-supported medications for secondary prevention of cardiovascular disease using qualitative analysis in 2 diverse countries across multiple levels of their health care systems.

The Authors found context-specific, health system factors that affect the patient's choice or ability to initiate and/or continue cardiovascular medication. Strategies to optimize cardiovascular drug use should be targeted and relevant to the health care system.

Reference

  • Miller V, Nambiar L, Saxena M, Leong D, Banerjee A, Werba JP, Faria Neto JR, Quinto KC, Moniruzzaman M, Khandelwal S. Exploring the Barriers to and Facilitators of Using Evidence-Based Drugs in the Secondary Prevention of Cardiovascular Diseases: Findings From a Multistakeholder, Qualitative Analysis. Glob Heart 2017 Nov 13. pii: S2211-8160(17)30080-7. doi: 10.1016/j.gheart.2017.08.001. [Epub ahead of print] Go to PubMed